In a nutshell This phase 1/2 trial is examining the effectiveness and safety of KY1044 alone and in combination with atezolizumab (Tecentriq) for patients with advanced cancers who are not suitable for any other treatment or have failed all other treatment options. The main outcomes to be measured will be the occurrence and severity of side effects and...
Read MorePerformance status-0 – Asymptomatic Posts on Medivizor
Searching for patients with advanced breast cancer to test a new T-cell treatment
In a nutshell This phase 2 trial will investigate the effectiveness of genetically-engineered cell treatment (GECT) in advanced cancer. The main outcome will be the response to treatment. This trial is recruiting at the National Cancer Institute, Maryland, US. The details There are limited treatment options for advanced cancer. One...
Read MoreLooking for participants with advanced colorectal cancer to test a new targeted treatment with DS-8201a
In a nutshell This phase 2 trial is examining the effectiveness and safety of DS-8201a in the treatment of advanced HER2 positive colorectal cancer. The main outcome to be measured is the tumor response to the treatment and side effects. The details The standard treatment to advanced colorectal cancers is surgery, chemotherapy and radiation...
Read MoreLooking for participants with stage 2 to 4 rectal cancer to try a new targeted therapy treatment
In a nutshell This phase 2 trial is examining the effectiveness and safety of durvalumab (Imfinzi) in the treatment of advanced rectal cancer that is not prone to genetic abnormalities. The main outcomes to be measured will be tumor response to the treatment and side effects. This trial is being conducted in the US. The details The standard treatment...
Read MoreLooking for patients with estrogen receptor-positive breast cancer to test a new treatment combination
In a nutshell This phase 2 trial will evaluate the safety and effectiveness of ribociclib (Kisqali) combined with hormonal therapy in patients with estrogen receptor-positive (ER+) breast cancer (BC). The main outcome will be the number of patients that complete 1 year of treatment and survival without signs of cancer. The trial will...
Read MoreSearching for patients with advanced HER2 positive breast cancer to test a breast cancer vaccine
In a nutshell This phase 2 trial will investigate the safety of pembrolizumab (Keytruda) in combination with VRP-HER2 vaccination in HER2-positive breast cancer (BC). The main outcomes will be the response of the immune system, clinical response, and side effects. This trial will be taking place in North Carolina, the U.S. The...
Read MoreLooking for patients with hormone-receptor positive breast cancer to test a new treatment combination
In a nutshell This phase 2 trial will investigate the safety of durvalumab (Imfinzi) in combination with standard hormonal treatment for breast cancer (BC). The main outcome will be the response to treatment. The trial is recruiting in Tampa, Florida, US. The details Breast cancer (BC) is one of the most common cancers. It affects bothe...
Read MoreEvaluating pembrolizumab versus platinum-based chemotherapy for advanced NSCLC
In a nutshell This study evaluated the effectiveness of pembrolizumab (Keytruda) versus platinum-based chemotherapy for patients with non-small cell lung cancer (NSCLC). This study found that pembrolizumab treatment resulted in longer overall survival than treatment with platinum-based chemotherapy. Some background NSCLC is the...
Read MoreLooking for patients with chronic lymphocytic leukemia to test acalabrutinib-obinutuzumab combination
In a nutshell This phase 2 trial is evaluating the effectiveness of acalabrutinib (Calquence) with or without obinutuzumab (Gazyva) for chronic lymphocytic leukemia (CLL). The main outcome to be measured will be the number of patients who have a complete disappearance of all signs of cancer. This study is being conducted in Phoenix, Arizona,...
Read MoreLooking for patients with small lymphocytic lymphoma to test acalabrutinib-obinutuzumab combination
In a nutshell This phase 2 trial is evaluating the effectiveness of acalabrutinib (Calquence) with or without obinutuzumab (Gazyva) for small lymphocytic lymphoma (SLL). The main outcome to be measured will be the number of patients who have a complete disappearance of all signs of cancer. This study is being conducted in Phoenix, Arizona, Jacksonville,...
Read MoreLooking for patients with advanced lung cancer to test a new drug
In a nutshell This phase 2 trial will investigate the safety and effectiveness of a new targeted therapy drug, INCMGA00012 in metastatic (spread to other organs) non-small cell lung cancer (NSCLC). The main outcome will be the overall response rate. This trial is recruiting in Texas, United States. The details NSCLC is the most common form of...
Read MoreLooking for patients with lung cancer to trial a new medication
In a nutshell This phase 3 trial will investigate the effectiveness of pembrolizumab (Keytruda) in non-small cell lung cancer (NSCLC). The main outcomes will be the rates of survival without any signs and symptoms of cancer and overall survival. The details NSCLC is usually treated with a combination of surgery to remove tumors and...
Read More
